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RHEUMATOID ARTHRITIS PATIENT EXPERIENCE WITH SELF-INJECTION WITH
SUBCUTANEOUS BIOLOGICS
Tandon N1, Ellis L1, Bolge S1, Iqbal R1, Buck L2
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Harris Interactive Inc., New York,
NY, USA
OBJECTIVES: To report patient experience with self-injection and describe injec-
tion site reactions and reasons for treatment compliance/discontinuation.
METHODS: In first quarter 2010, RA patients completed a cross-sectional, self-
administered, Internet-based questionnaire. In the survey, SC was defined as
“medication administered via needle just under the skin”. Data were weighted to
reflect general population proportions for age, gender, race, education, household
income and region. RESULTS: Of 58 SC biologic patients, 67% experienced pain
during or after receiving injections. On a scale from 1-10 describing severity of pain
( 1 “not at all painful” and 10 “extremely painful”), 9% during injection and 22%
after injection rated severity of pain as 8. Stinging, bruising, pain, redness, burn-
ing and swelling were the most common injection site reactions experienced by
biologic users. Of these patients, 21% experienced at least one or more of these
symptoms ‘most or all the time’. Among the 58 SC biologic patients, 41% were
‘somewhat willing’, 12% were ‘very willing” and 8% were ‘extremely willing’ to
switch treatments as a result of injection site reactions. Among SC patients who
self-reported that they did not take biologics as prescribed, 22% described injection
fear and another 22% described general fear of needles as “very influential” in not
complying with their treatment. 19% of patients who discontinued SC biologics
(n55) cited ‘felt uncomfortable about needles” as ‘very influential’ and ‘extremely
influential’ reasons for discontinuation. CONCLUSIONS: In this analysis, many
patients experience injection related pain associated with SC biologics and this
may be impacting therapy compliance and continuation. Therefore, it may be im-
portant to evaluate different injection options within SC biologics when making
treatment selection and patient access decisions. Given the small sample size
(n58), further research is needed to quantify impact of injection experience on
self-reported vs. observed compliance and treatment continuation.
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EARLY AND SUSTAINED REMISSION ASSOCIATED WITH NORMALIZED
PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE AND
SIGNIFICANTLY IMPROVED PRODUCTIVITY IN PATIENTS WITH ACTIVE
PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB: TWO YEAR DATA FROM
THE PHASE III GO-REVEAL CLINICAL TRIAL
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OBJECTIVES: Evaluate golimumab’s(GLM) impact on disease remission, physical
function, work productivity and healthcare utilization in patients with psoriatic
arthritis (PsA) over 2 yrs.METHODS: In GO-REVEAL, 405 adultswith active PsAwere
randomized to GLM(50 or 100 mg) q4wks or placebo. At wk16, patients with inad-
equate response entered early escape. All placebo-treated patients received
GLM50mg fromwk24. Clinical responses parameters included 20% improvement in
American College of Rheumatology (ACR20) criteria, 75% improvement in Psoriasis
Area and Severity Index(PASI75); a disease activity score (DAS28) 2.6 defined re-
mission. Patient-reported outcomes included health assessment questionnaire
(HAQ), self-reported productivity and medical visits. Comparisons between GLM
and placebo before wk24 employed ANOVA on van der Waerden normal scores
(continuous outcomes) or Chi-square test (categorical). RESULTS: Baseline HAQ
and PASI scores were 1.02 and 7.8. A greater proportion of GLM- than placebo-
treated patients achieved DAS28 remission by wk4(16.3% vs. 3.6%, p0.001) and
wk14 (30.6% vs. 1.9%, p0.001). Remission rates increased over time, exceeding 50%
for GLM-treated patients at wk104. Greater proportions of GLM-treated patients
achieved ACR20 and PASI75 responses, normalized HAQ (0.5) or health-related
quality-of-life (HRQoL), or significantly improved work productivity versus placebo
at wk14 (all p0.01). These improvements were sustained through wks52 and 104.
A greater proportion of patients achieving versus not achieving DAS28 remission
also achieved normalized physical function or had significantly improved work
productivity from baseline at wks52 and 104. Improvements in employability, time
lost fromwork by patients and caregivers and healthcare utilizationwere observed
at wks52 and 104, especially among patients achieving DAS28 remission. The over-
all GLM safety profile through wk104 was similar to other anti-TNF agents indi-
cated for PsA. CONCLUSIONS: GLM treatment induced early and sustained remis-
sion (DAS282.6), resulting in long-term improvements in physical function, QoL,
and work productivity and reduced healthcare utilization, in PsA patients.
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FREQUENCY OF SELECT ANTI-TNF ADMINISTRATION OR RE-FILL IN PATIENTS
WITH RHEUMATOID ARTHRITIS
Schmeichel-Mueller C1, Bartels A2, Silver J2, Bolge S1, Ingham M1
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OBJECTIVES: Limited information exists on real-world patient adherence to the
FDA recommended prescribing schedules for adalimumab (ADA) (40 mg bi-
weekly), etanercept (ETA) (50 mg/week), and infliximab (IFX) (every 8 or 4 weeks
following induction) in the treatment of patients with rheumatoid arthritis (RA).
This study evaluates the days between infusions for IFX and refills for ADA and
ETA. METHODS: Data between 01/2004-12/2007 were extracted from a retrospec-
tive multi-source claims database. Inclusion criteria were aged 18, 2 diagnoses
of RA (ICD-9 code 714.xx), 1 claim for biologic therapy, absence of any biologic
claim for 12 months prior to index date, and absence of any biologic claim other
than the index biologic for 730 days post-index date. Patients with diagnoses of
other selected inflammatory disorders were excluded. IFX patients were required
to have4 doses. Days between infusions or re-fills for the first 12 infusions of IFX
and fills of ADA and ETA are reported. Time to re-fill was calculated as the differ-
ence between fill dates minus days supply. RESULTS: Intervals between IFX infu-
sions during the maintenance period ranged from a mean of 52.3 to 55.0 days over
the first 12 infusions. Refills for ADA ranged from amean of 7.3 to 11.4 days beyond
recommended refill schedule over the first 12 prescription fills. Refills for ETA
ranged from a mean of 6.7 to 14.2 days beyond the recommended refill schedule.
CONCLUSIONS: Data from real-world community practice indicate that patients
treated with IFX are infused at intervals consistent with prescribing information
and patients undergoing treatment with ADA and ETA are refilling prescriptions
one to two weeks later than the recommended refill schedule. Further studies are
warranted to understand the clinical implications of gaps in therapywith themore
frequently dosed subcutaneous agents vs. the less frequently dosed infused med-
ications such as IFX.
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ANALYSIS OF INFLIXIMAB DOSE CHANGES OVER TIME IN MEDICARE
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OBJECTIVES: To describe patient level infliximab (IFX) dosing changes over time
duringmaintenance treatment inMedicare Beneficiarieswith rheumatoid arthritis
(RAMB).METHODS: This retrospective claims analysis used the 2001-2008 Centers
for Medicare and Medicaid Services (CMS) Medicare Beneficiary 5% Standard Ana-
lytical Files. This database includes Medicare beneficiaries that are eligible due to
age (65 years) or other criteria such as disability or end-stage renal disease. In-
clusion criteria included RAMBs receiving 8 and 12 consecutive quarters of IFX
treatment, a diagnosis of RA, and no IFX treatment during the preceding quarter.
IFX dosing was analyzed at the patient level to determine the dosing change from
quarter to quarter, not including the first quarter of IFX treatment. IFX dosing was
determined from theMedicare billing units submitted for payment.Meanquarterly
per patient IFX dose was determined by dividing the total infliximab unit amount
by the number of administrations per quarter. RESULTS: A total of 395 RAMBs
receiving IFXwere identified. Mean agewas 67.5 years, and 75%were female. Mean
IFX dose was 380mg andmean treatment duration was 9.7 quarters. Themean IFX
dose increase was 11.7 mg per quarter. IFX dosing changes over time: 41% had no
change or an IFX dose decrease, 35% had a dose increase of  20 mg per quarter,
19% had a dose increase of  20 and  40 mg per quarter, and 5% had a dose
increase of  40 mg per quarter. CONCLUSIONS: This patient level analysis of
maintenance IFX dosing in RAMBs observedminimal dose escalation, with only 5%
of RAMBS requiring more than 40 mg IFX dose increase per quarter over 2-3 years
of IFX treatment. Nearly half of RAMBs had no dose increase, or a decrease in IFX
dose during maintenance treatment.
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Brooks-Rooney C, Costello S, Kusel J, Timm B
Costello Medical Consulting Ltd, Cambridge, UK
BACKGROUND: Comparative effectiveness research is seen as a powerful tool to
assist payers in determining the most effective treatment option when multiple
possibilities exist. Whilst head-to-head trials of relevant comparator treatments
are uncommon, indirect comparisons, such as Mixed Treatment Comparisons
(MTCs), offer the potential to help assess the comparative efficacy of therapies,
which can inform payers about their comparative effectiveness. OBJECTIVES: To
review the use of MTCs in published technology appraisals from the National In-
stitute for Health and Clinical Excellence (NICE) in the UK. METHODS: All NICE
technology appraisals from January 2006 to December 2010 were searched for
‘mixed treatment comparison’. RESULTS: Overall, 17 appraisals containing MTCs
were identified. Of these, 24%were for rheumatoid arthritis, 24% for cardiovascular
conditions, 18% for cancer and the remainder were for other conditions. In 2010,
NICE published 26 appraisals, of which 8 (30.8%) utilised MTCs; in 2009, 26% of
appraisals (5/19) incorporatedMTCs; in 2008 this figurewas 17.4% (4/23) and in 2007
and 2006 no appraisals, out of 19 and 14 published appraisals respectively, con-
tainedMTCs. The justification inmost cases for the use of theMTCswas to provide
an indication of comparative effectiveness for the intervention compared with
major competitors and often the findings were incorporated into the manufactur-
er’s economic model. However, in the majority of appraisals, the Evidence Review
Group criticised the design of the MTCs, and in at least 5 cases this led to the
Committee either disregarding the results of the MTC or interpreting them with
caution.CONCLUSIONS:The value ofMTCs for determining comparative effective-
ness in Health Technology Assessments cannot be disputed, and they are increas-
ingly becoming a more common feature in the NICE appraisal process. However,
manufacturers should ensure that their MTCs are robustly designed otherwise the
success of their submission may be jeopardised.
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